agenT-797
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Multiple Myeloma
Conditions
Relapsed/Refractory Multiple Myeloma
Trial Timeline
Mar 29, 2021 → May 31, 2023
NCT ID
NCT04754100About agenT-797
agenT-797 is a phase 1 stage product being developed by MiNK Therapeutics for Relapsed/Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT04754100. Target conditions include Relapsed/Refractory Multiple Myeloma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Multiple Myeloma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04754100 | Phase 1 | Completed |
| NCT04582201 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Multiple Myeloma